Indazole-pyrazole skeleton compound and application thereof
By synthesizing an indazole-pyrazole skeleton compound, the side effects of existing PDE4 inhibitors were resolved, achieving highly efficient inhibition of PDE4B and in vivo anti-inflammatory effects, especially significant efficacy in an acute lung injury model.
Patent Information
- Application Number
- CN202411121623.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-15
AI Technical Summary
Existing PDE4 inhibitors have gastrointestinal and central nervous system side effects when treating inflammation, fibrosis, and central nervous system diseases, necessitating the development of novel PDE4 inhibitors to improve therapeutic index and selectivity.
An indazole-pyrazole backbone compound was designed and synthesized that activates cAMP-dependent protein kinase A by regulating cAMP levels, thereby regulating related physiological and pathological processes and providing PDE4B and/or PDE4D inhibitors.
The compound exhibits highly efficient inhibitory activity against PDE4B, with significant in vitro enzyme activity and in vivo anti-inflammatory effects, particularly demonstrating good efficacy in an acute lung injury model, including inhibition of inflammatory factor release and tissue repair.
Smart Images

Figure CN119019333A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to an indazole-pyrazole skeleton compound and application thereof. Background Art
[0002] Phosphodiesterase 4 (PDE4) belongs to the phosphodiesterase family. It is responsible for degrading cyclic adenosine monophosphate (cAMP) in the body. It is the earliest discovered protein in the phosphodiesterase family and has the largest number of members. It regulates the level of intracellular cAMP together with nucleotide cyclase and plays a key role in the homeostasis of cAMP signaling. PDE4 contains four subtypes: A, B, C and D. Among them, subtype C is less expressed in the body. The main subtypes are A, B and D. Each subtype has significant expression differences in different tissues and organs. The subtypes that are currently studied more are B and D. After different splicing, each subtype gene forms a variety of splice variants. According to the upstream conserved regions (UCRs), they can be divided into long, short, ultra-short and dead short types. Among them, the long type of PDE4 contains UCR1 and UCR2, the short type contains only UCR2, and the ultrashort type contains truncated UCR2. Each PDE4 subtype and splicing variant may have its own unique function.
[0003] cAMP is an important signaling molecule that regulates important physiological and pathological processes such as inflammatory response, fibrosis, body damage, and central nervous system function. It can affect the occurrence and development of inflammation, the formation of fibrosis, inflammation and repair after injury, neurogenesis, the establishment of neuronal circuits, cell apoptosis, neural plasticity, sleep, sensory motor gating, emotional stability, memory, and other cognitive functions. As one of the important members regulating cAMP signals, PDE4 has attracted much attention in recent years in the treatment of diseases such as inflammation, fibrosis, damage, and the central nervous system. Related diseases include inflammatory diseases such as chronic obstructive pulmonary disease, asthma, dermatitis, hepatitis, non-alcoholic fatty liver disease, psoriasis, rhinitis, Behcet's syndrome, arthritis, eczema, vitiligo, and ulcerative colitis; fibrotic diseases such as pulmonary fibrosis, liver fibrosis, and cystic fibrosis; injury-related diseases such as lung injury, liver injury, kidney injury, edema, and traumatic brain injury; central nervous system diseases such as Alzheimer's disease, anti-depression, anti-anxiety, multiple sclerosis, stroke, and cognitive improvement.
[0004] PDE4 participates in a variety of physiological functions and is closely related to a variety of diseases by regulating the level of cAMP in the body. The main pathways involved in PDE4 include the cAMP / PKA / CREB signaling pathway and the MAPK / ERK / CREB pathway. By inhibiting the activity of PDE4, the hydrolysis of cAMP is blocked, the cellular level increases, and then activates cAMP-dependent protein kinase A (PKA), activates the cAMP / PKA / CREB and / or MAPK / ERK / CREB signaling pathways, and then regulates the expression of a variety of target genes including BDNF, Bax, PEPCK, IL-2, etc., thereby participating in a variety of physiological and pathological processes related to inflammation, fibrosis, injury, memory and learning.
[0005] A large number of clinical and preclinical studies have shown that regulating PDE4 activity and cAMP levels through inhibitors can play a role in treating a variety of diseases. Currently, there are many PDE4 inhibitors on the market, including roflumilast, apremilast, and criborol. Due to the problems of gastrointestinal side effects and central nervous system side effects of marketed drugs, PDE4 inhibitors are still a hot topic of research. Improving the therapeutic index is the main research goal. The main research directions include changing the route of administration, discovering highly active subtype selective inhibitors, dual-target inhibitors, discovering inhibitors that are difficult to penetrate the blood-brain barrier, and indication research.
[0006] The above studies show that PDE4 is a druggable target with great potential and has great therapeutic potential in the fields of inflammatory diseases, fibrosis-related diseases, injury-related diseases and central nervous system-related diseases. It is urgent to develop new PDE4 inhibitors for the development of candidate drugs for related diseases. Summary of the invention
[0007] A compound as shown in formula I or a pharmaceutically acceptable salt thereof,
[0008]
[0009] Among them, Z is
[0010] X is O or NR 5 ;
[0011] R 1 and R 5 are independently hydrogen, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;
[0012] R 2 is hydrogen, unsubstituted or replaced by R 2-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 2-2Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 2-3 Substituted 3-6 membered heterocycloalkyl;
[0013] R 3 and R 4 are independently hydrogen, halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy;
[0014] R 1-1 and R 2-1 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkoxy, C 1-4 Haloalkoxy;
[0015] R 2-2 and R 2-3 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 carboxyl;
[0016] R 5 and R 6 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy;
[0017] n1 is 0, 1, 2 or 3;
[0018] n2 is 0, 1, 2, 3 or 4.
[0019] In some embodiments, in the compound of Formula I or a pharmaceutically acceptable salt thereof, X is O;
[0020] R 1 is hydrogen, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl;
[0021] R 2 is hydrogen, unsubstituted or replaced by R 2-1 Substituted C 1-6 alkyl;
[0022] R 3 and R 4are independently hydrogen, halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy;
[0023] R 1-1 and R 2-1 Each is independently halogen, hydroxy, amino, nitro, cyano;
[0024] R 2-2 and R 2-3 are independently halogen, hydroxy, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy.
[0025] In some embodiments, X is O.
[0026] In some embodiments, R 1 is hydrogen, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl.
[0027] In some embodiments, R 1 is unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl.
[0028] In some embodiments, R 1 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
[0029] In some embodiments, R 1 It is hydrogen, methyl, ethyl, n-propyl, isopropyl.
[0030] In some embodiments, R 1 It is ethyl.
[0031] In some embodiments, R 2 is hydrogen, unsubstituted or replaced by R 2-1 Substituted C 1-6 alkyl.
[0032] In some embodiments, R 2 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
[0033] In some embodiments, R 2 It is hydrogen, methyl, ethyl, n-propyl, isopropyl.
[0034] In some embodiments, R 2 For hydrogen.
[0035] In some embodiments, R 3 and R 4 are independently hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy.
[0036] In some embodiments, R 3 and R 4 are independently hydrogen, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy.
[0037] In some embodiments, R 3 and R 4 For hydrogen.
[0038] In some embodiments, R 1-1 and R 2-1 Each is independently halogen, hydroxy, amino, nitro, or cyano.
[0039] In some embodiments, R 2-2 and R 2-3 are independently halogen, hydroxy, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy.
[0040] In some embodiments, n1 is 0.
[0041] In some embodiments, n2 is 0.
[0042] In some embodiments, R 1 , R 2 and R 5 In the C 1-6 The alkyl groups are each independently C 1-4 Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
[0043] In some embodiments, R 2 wherein the 3-6 membered cycloalkyl groups are each independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0044] In some embodiments, R 2 In the above, the 3-6 membered heterocycloalkyl groups are each independently a 3-6 membered heterocycloalkyl group having "a heteroatom selected from one or more of N, O and S, and the number of heteroatoms is 1, 2 or 3".
[0045] In some embodiments, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 wherein the halogen is independently fluorine, chlorine or bromine.
[0046] In some embodiments, R 3 , R 4 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
[0047] In some embodiments, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkyl groups in the haloalkyl group are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
[0048] In some embodiments, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The halogen in the haloalkyl group is independently fluorine, chlorine or bromine. 3 , R 4 , R 1-1 , R 2-1 , R 2-2 and R 2-3 In the C 1-4 The halogen in the haloalkyl group is independently fluorine.
[0049] In some embodiments, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3, R 5 and R 6 In the C 1-4 The alkyl groups in the haloalkyl group are each independently -CF 3 , -CHF 2 or -CH 2 F.
[0050] In some embodiments, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkoxy groups are each independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
[0051] In some embodiments, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkoxy groups in the haloalkoxy groups are each independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
[0052] In some embodiments, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The halogen in the haloalkoxy group is independently fluorine, chlorine or bromine.
[0053] In some embodiments, the compound of Formula I or a pharmaceutically acceptable salt thereof is any of the following structures:
[0054]
[0055]
[0056] The present disclosure provides a pharmaceutical composition, which includes the compound shown in the above formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0057] The present disclosure also provides a use of the compound as shown in Formula I or a pharmaceutically acceptable salt thereof or the pharmaceutical composition in the preparation of a medicament as a PDE4 inhibitor. In some embodiments, the PDE4 inhibitor is a PDE4B and / or PDE4D inhibitor.
[0058] The present disclosure also provides a use of the above-mentioned compound as shown in Formula I or its pharmaceutically acceptable salt or the above-mentioned pharmaceutical composition in the preparation of a drug for preventing and / or treating a disease related to PDE4. In some embodiments, the PDE4 is PDE4B and / or PDE4D. In some embodiments, the disease related to PDE4 is an inflammatory disease, a fibrotic disease, a damaging disease, and a central nervous system disease. In some embodiments, the inflammatory disease includes chronic obstructive pulmonary disease, asthma, dermatitis, hepatitis, non-alcoholic fatty liver disease, psoriasis, rhinitis, Behcet's syndrome, arthritis, eczema, vitiligo, and ulcerative colitis. In some embodiments, the fibrotic disease includes pulmonary fibrosis, liver fibrosis, and cystic fibrosis. In some embodiments, the damaging disease includes lung injury, liver injury, kidney injury, edema, and traumatic brain injury. In some embodiments, the central nervous system disease includes Alzheimer's disease, antidepression, anti-anxiety, multiple sclerosis, stroke, and cognitive impairment-related diseases. In some embodiments, the disease related to PDE4 is acute lung injury.
[0059] The present disclosure also provides a compound as shown in Formula I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as shown in Formula I for the preparation of a drug for preventing and / or treating a disease, wherein the disease is an inflammatory disease, a fibrotic disease, a damaging disease, and a central nervous system disease. In some embodiments, the inflammatory disease includes chronic obstructive pulmonary disease, asthma, dermatitis, hepatitis, nonalcoholic fatty liver disease, psoriasis, rhinitis, Behcet's syndrome, arthritis, eczema, vitiligo, and ulcerative colitis. In some embodiments, the fibrotic disease includes pulmonary fibrosis, liver fibrosis, and cystic fibrosis. In some embodiments, the damaging disease includes lung injury, liver injury, kidney injury, edema, and traumatic brain injury. In some embodiments, the central nervous system disease includes Alzheimer's disease, antidepression, antianxiety, multiple sclerosis, stroke, and improved cognition. In some embodiments, the disease is acute lung injury.
[0060] The present disclosure also provides a compound as shown in Formula II or a pharmaceutically acceptable salt thereof,
[0061]
[0062] Wherein, Y is nitro or amino; Z, R 5 and n1 is defined as in any embodiment of the compound of formula I.
[0063] In some embodiments, the compound shown in Formula II is any of the following structures:
[0064]
[0065]
[0066] The present disclosure also provides a method for preparing the compound as shown in Formula I, which comprises the following steps:
[0067] (1) reacting a compound represented by formula IV with a compound represented by formula V to obtain a compound represented by formula II-1;
[0068] (2) subjecting the compound represented by formula II-1 to reduction reaction to obtain the compound represented by formula II-2;
[0069] (3) reacting the compound represented by formula II-2 with the compound represented by formula III to obtain the compound represented by formula I;
[0070]
[0071] Among them, A 1 and A 2 are independently halogen; Z, R 2 , R 5 , R 6 , n1 and n2 are defined as in any embodiment of the compound represented by Formula I.
[0072] Definition of terms
[0073] In the case where the present disclosure does not limit a specific configuration, the disclosed compounds may exist in specific geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, all of which are within the scope of the present disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present disclosure.
[0074] Compounds and intermediates of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also referred to as prototransfer tautomers) include interconversion via proton migration, such as keto-enol and imine-enamine, lactam-lactim isomerization. Lactam-lactim equilibrium examples are between A and B as shown below.
[0075]
[0076] All compounds in the present disclosure can be drawn as either Form A or Form B. All tautomeric forms are within the scope of the present disclosure. The naming of the compounds does not exclude any tautomers.
[0077] The disclosed compounds may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The disclosed compounds containing asymmetric carbon atoms may be isolated in optically pure forms or in racemic forms. Optically pure forms may be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
[0078] Optically active (R)- and (S)-isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary groups are cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is usually accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., the formation of a carbamate from an amine).
[0079] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 30 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 10 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and further preferably an alkyl group containing 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like.
[0080] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 7 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.; polycyclic cycloalkyls include spirocyclic, fused and bridged cycloalkyls.
[0081] The term "heterocycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more ring atoms is selected from nitrogen, oxygen, C(=O) or S(=O). m (wherein m is an integer from 0 to 2) heteroatoms, but does not include -OO-, -OS- or -SS- ring parts, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 7 ring atoms. Non-limiting examples of monocyclic heterocycloalkyls include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocycloalkyls include spirocyclic, fused ring and bridged heterocycloalkyls. Non-limiting examples of "heterocycloalkyls" include:
[0082]
[0083] etc.
[0084] The heterocycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a heterocycloalkyl, non-limiting examples of which include:
[0085] wait.
[0086] The term "alkoxy" refers to an -O-(alkyl) group, wherein alkyl is as defined above.
[0087] The term "hydroxy" refers to -OH.
[0088] The term "thiol" refers to -SH.
[0089] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0090] The term "haloalkyl" refers to an alkyl group substituted with a halogen, wherein alkyl is as defined above.
[0091] The term "cyano" refers to -CN.
[0092] The term "nitro" refers to -NO 2 .
[0093] The term "amino" refers to -NH 2 .
[0094] The term "carboxy" refers to -C(O)OH.
[0095] The term "substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort.
[0096] "Substituted by one or more..." means that the compound may be substituted by a single or multiple substituents. When substituted by multiple substituents, the substituents may be the same or a combination of one or more different substituents.
[0097] The term "linked", when referring to a connection between two molecules, means that the two molecules are connected by a covalent bond or the two molecules are associated via a non-covalent bond (eg, a hydrogen bond or an ionic bond), including direct and indirect connections.
[0098] The term "directly connected" refers to a first compound or group connected to a second compound or group without any intervening atoms or groups of atoms. The term "indirectly connected" refers to a first compound or group connected to a second compound or group through an intermediate group, compound or molecule (e.g., a linking group).
[0099] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if there are chiral isomers in the chemical structure, the bond Can be or include both Although all of the above structural formulas are drawn as certain isomers for simplicity, the present disclosure may include all isomers, such as tautomers, rotational isomers, geometric isomers, diastereomers, racemates and enantiomers. In the chemical structures of the compounds described in the present disclosure, the bonds No configuration is specified, i.e., the bond The configuration can be E-type or Z-type, or include both E and Z configurations.
[0100] Unless otherwise specified, the symbols used in this article are It means that it can be connected to one or more any groups according to the disclosure described herein.
[0101] In the present disclosure, the terms "comprising" and "including" may be replaced with "consisting of".
[0102] The term "composition" refers to a mixture of a drug and other chemical components containing one or more compounds described herein or their physiologically pharmaceutically acceptable salts or precursors, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. The purpose of the composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.
[0103] The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable excipient" includes, but is not limited to, any adjuvant, carrier, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the U.S. Food and Drug Administration for use in humans or livestock animals.
[0104] Unless otherwise specified, the "compounds" of the present disclosure may exist independently in the form of salts, mixed salts or non-salts (such as free acids or free bases). When they exist in the form of salts or mixed salts, they may be pharmaceutically acceptable salts or pharmaceutically usable salts.
[0105] The terms "pharmaceutically acceptable salts" and "pharmaceutically acceptable salts" are used interchangeably and are meant to include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0106] "Pharmaceutically acceptable acid addition salt" refers to a salt formed with an inorganic acid or an organic acid which retains the biological effectiveness of the free base without other adverse effects and can be prepared by methods known in the art.
[0107] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base which can retain the biological effectiveness of the free acid without other adverse effects. These salts can be prepared by methods known in the art.
[0108] "Effective amount," "effective dose," "therapeutically effective amount," or "therapeutically effective amount" refers to the amount of a drug, compound, or pharmaceutical composition necessary to achieve any one or more beneficial or desired therapeutic results. For prophylactic uses, beneficial or desired results include eliminating or reducing the risk, lessening the severity, or delaying the onset of a condition, including biochemical, histological, and / or behavioral symptoms of the condition, its complications, and intermediate pathological phenotypes present during the development of the condition.
[0109] As used herein, "subject," "patient," "subject," or "individual" are used interchangeably and include humans or non-human animals, such as mammals, such as humans or monkeys. BRIEF DESCRIPTION OF THE DRAWINGS
[0110] Figure 1 The results are the anti-inflammatory activity of the compounds at the cell level in vitro.
[0111] Figure 2 These are the results of lung tissue sections in the compound's acute lung injury efficacy test.
[0112] Figure 3These are the results of the efficacy index test of the compound in acute lung injury efficacy test, including (a) lung dry-to-wet weight ratio result; (b) lavage fluid neutrophil count result; (c) MPO determination result; (d) NO determination result; (e) TNF-α content determination result in lavage fluid; (f) IL-1β content determination result in lavage fluid; (g) IL-6 content determination result in lavage fluid. Specific implementation plan
[0113] The present disclosure is further described below in conjunction with examples, but these examples are not intended to limit the scope of the present disclosure. Experimental methods in the examples of the present disclosure that do not specify specific conditions are generally performed under conventional conditions or under conditions recommended by raw material or commodity manufacturers. Reagents that do not specify specific sources can be obtained from any supplier of molecular biology reagents with quality / purity for molecular biology applications.
[0114] Unless otherwise specified, the reagents used in the following examples are commercially available products.
[0115] Example 1
[0116] Step 1. 3-Bromo-1-(2,2-difluoroethyl)-5-nitro-1H-indazole
[0117]
[0118] The raw material 3-bromo-5-nitroindazole (3.00g, 12.40mmol, 1.00eq) was placed in a 100mL round-bottom flask, anhydrous acetonitrile (10mL) was used as solvent, and then 1,1-difluoro-2-iodoethane (1637μl, 18.60mmol, 1.50eq) and potassium carbonate (571mg, 4.14mmol, 2.00eq) were added in sequence, and heated to reflux at 85°C for 12h. After the reaction was completed by TLC detection, the reaction solution was cooled to room temperature, filtered through diatomaceous earth, the organic phase was distilled under reduced pressure and dried, ethyl acetate was redissolved, and water was added and extracted with ethyl acetate three times (20ml×3), the organic phase was collected and washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5h, and the solvent was evaporated under reduced pressure, wet column was loaded, and column chromatography purification (petroleum ether: dichloromethane = 8:1) was obtained to obtain 2.99g of light yellow solid powder product, with a yield of 79%.
[0119] 1 HNMR (300 MHz, DMSO-d 6 )δ8.50(d,J=1.6Hz,1H),8.37(dd,J=9.3,2.2Hz,1H),8.02(d,J=9.7Hz,1H),6.49(tt,J=54.3,3.3Hz,1H),5.09(td,J=15.5,3.3Hz,2H)ppm.
[0120] Step 2. Preparation of 1-(2,2-difluoroethyl)-3-(1-ethyl-1H-pyrazol-5-yl)-5-nitro-1H-indazole
[0121]
[0122] The intermediate (380 mg, 1.25 mmol, 1.00 eq) and 1-ethylpyrazole-5-boric acid (456 mg, 3.26 mmol, 2.00 eq) were placed in a 50 mL two-necked flask, dissolved in a mixed solvent of toluene (8 mL) and methanol (4 mL), and then 2 mL of sodium carbonate (532 mg, 5.02 mmol, 4.00 eq) aqueous solution was added. After vacuuming for 5 min, the catalyst [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (92 mg, 0.13 mmol, 0.1 eq) was added, and vacuuming was continued for 10 min. Under nitrogen protection, the mixture was heated to reflux at 100 ° C for 14 h. After the reaction was completed, the reaction solution was cooled to room temperature and filtered using diatomaceous earth. The organic solvent was evaporated under reduced pressure, and an appropriate amount of water was added and extracted with ethyl acetate three times (30 mL×3). The organic phases were collected and combined, washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5 h, concentrated under reduced pressure and then sanded, and purified by column chromatography (petroleum ether: ethyl acetate = 32:1) to obtain 210 mg of a light yellow solid powder product with a yield of 40%.
[0123] 1 HNMR (300 MHz, DMSO-d 6 )δ8.74(d,J=1.5Hz,1H),8.38(dd,J=9.3,2.1Hz,1H),8.06(d,J=9.3Hz,1H),7.68(d,J=2.0Hz,1H),7.05(d,J=2.0H z,1H),6.56(tt,J=54.3,3.2Hz,1H),5.17(td,J=15.6,3.2Hz,2H),4.52(q,J=7.1Hz,2H),1.35(t,J=7.1Hz,3H)ppm.
[0124] Step 3. Preparation of 1-(2,2-difluoroethyl)-3-(1-ethyl-1H-pyrazol-5-yl)-1H-indazol-5-amine
[0125]
[0126] The intermediate (270 mg, 0.79 mmol, 1.00 eq) was placed in a 50 mL single-necked flask, dissolved in a mixed solvent of ethanol (12 mL) and water (6 mL), and then iron powder (177 mg, 3.17 mmol, 4.00 eq) and ammonium chloride (423 mg, 7.92 mmol, 10.00 eq) were added in sequence, and heated to reflux at 80 ° C for 4 h. After the reaction was completed by TLC detection, it was filtered while hot, and an appropriate amount of water was added to the filtrate, and then extracted with dichloromethane three times (30 mL×3), the organic phases were combined and washed twice with a saturated sodium chloride solution, dried over anhydrous sodium sulfate for 0.5 h, and concentrated under reduced pressure to obtain 170 mg of a reddish brown flaky solid product with a yield of 89%.
[0127] 1 HNMR (300 MHz, DMSO-d 6 )δ7.59(d,J=1.9Hz,1H),7.52(d,J=9.5Hz,1H),7.00–6.86(m,2H),6.66(d,J=1.9Hz,1H),6.44(tt,J=54. 8,3.6Hz,1H),5.29(s,2H),4.89(td,J=15.2,3.6Hz,2H),4.50(q,J=7.1Hz,2H),1.33(t,J=7.1Hz,3H)ppm.
[0128] Step 4. Preparation of ethyl (4-((1-(2,2-difluoroethyl)-3-(1-ethyl-1H-pyrazol-5-yl)-1H-imidazol-5-yl)amino)phenyl)acetate (Compound 2)
[0129]
[0130] The intermediate (210 mg, 0.68 mmol, 1.00 eq) and methyl p-bromophenylacetate (118 μl, 0.75 mmol, 1.10 eq) were placed in a 25 mL two-necked bottle and dissolved with anhydrous toluene (6 mL) as a solvent. Cesium carbonate (440 mg, 1.35 mmol, 2.00 eq) and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (84 mg, 0.135 mmol, 0.20 eq) were added in sequence. After vacuuming for 5 min, palladium acetate (15 mg, 0.068 mmol, 0.10 eq) was added, and vacuuming was continued for 10 min. Under nitrogen protection, the mixture was heated at 100 ° C for 20 h under reflux. After the reaction was completed, the reaction solution was cooled to room temperature and filtered using diatomaceous earth. The organic solvent was evaporated under reduced pressure, and an appropriate amount of water was added before extraction with ethyl acetate three times (30 mL×3). The organic phases were collected and combined, washed twice with saturated brine, dried over anhydrous sodium sulfate for 0.5 h, concentrated under reduced pressure, and sanded. The product was purified by column chromatography (petroleum ether: ethyl acetate = 16:1) to obtain 85 mg of a yellow solid powder product with a yield of 49%.
[0131] MP150-153℃. 1 HNMR (300 MHz, DMSO-d 6 )δ8.19(s,1H),7.74(d,J=9.0
[0132] Hz,1H),7.60(d,J=1.9Hz,1H),7.43(d,J=1.9Hz,1H),7.31(dd,J=9.0,2.0Hz,1H),7.11(d,J=8.5Hz,2H),7.01(d,J=8.6Hz,2H),6.69(d,J =1.9Hz,1H),6.68–6.30(m,1H),4.98(td,J=15.3,3.5Hz,2H),4.50(q,J=7.1Hz,2H),3.60(s,3H),3.56(s,2H),1.35(t,J=7.1Hz,3H)ppm. 13 C NMR (101 MHz, CDCl 3 )δ172.51,143.35,138.75,137.89,137.82,135.97,133.45,130.35,125.89,123.74,122.94,116.61,116. 30,113.87,111.44,110.12,109.04,106.37,52.07,51.33(t,J=28.3Hz),45.99,40.40,15.72ppm.HRMS(ESI + ):m / z[M+H] +calculated for C 23 H 23 F 2 N 5 O 2 ,440.1898; found440.1891.HPLC purity=95.02%,t R =14.44min.
[0133] Step 5. Preparation of 2-(4-((1-(2,2-difluoroethyl)-3-(1-ethyl-1H-pyrazol-5-yl)-1H-imidazol-5-yl)aminophenyl)acetic acid (Compound 1)
[0134]
[0135] Compound 2 (95 mg, 0.21 mmol, 1.00 eq) was dissolved in 3 mL of methanol, and then 2 mL of KOH (33 mg, 0.83 mmol, 4.00 eq) aqueous solution was added, and the mixture was heated to reflux at 80°C for 4 h. After the reaction was completed by TLC detection, the solvent was removed by distillation under reduced pressure, and after adding an appropriate amount of water, the pH was adjusted to 1-2 with a dilute hydrochloric acid solution (1 mol / L), and then extracted with ethyl acetate three times (20 mL×3), and the organic phases were collected and combined, dried over anhydrous sodium sulfate for 0.5 h, concentrated under reduced pressure, and sanded, and purified by column chromatography (dichloromethane: methanol = 80: 1) to obtain 22 mg of a light yellow powdery solid product with a yield of 54%.
[0136] MP139-140℃. 1 H NMR (300 MHz, DMSO-d 6 )δ11.70(s,1H),8.16(d,J=5.9
[0137] Hz,1H),7.73(d,J=9.0Hz,1H),7.59(s,1H),7.43(s,1H),7.30(d,J=9.1Hz,1H),7.20–7.05(m,2H),7.01(d,J=8.3Hz,2H),6.68(d,J= 6.6Hz,1H),6.49(tt,J=54.6,3.6Hz,1H),4.98(td,J=15.2,3.4Hz,2H),4.50(q,J=7.1Hz,2H),3.45(s,2H),1.35(t,J=7.0Hz,3H)ppm. 13C NMR (101MHz, DMSO) δ173.68,143.30,139.04,138.91,137.53,134.65,133.70,130.66,126.28,123.06,122.03,1 17.65,117.29,116.35,114.89,112.49,111.74,106.14,105.30,50.71(t,J=25.3Hz),45.75,16.11ppm.HRMS(ESI + ):m / z[M+H] + calculated for C 22 H 21 F 2 N 5 O 2 ,426.17416; found 426.17300.HPLC purity=98.07%,t R =8.31min.
[0138] Test Example 1: PDE4 Inhibitory Activity Test
[0139] The specific test method is as follows:
[0140] Compound solution preparation:
[0141] Through calculation, 0.005 mmol of each test compound was accurately weighed and dissolved in 0.5 mL of DMSO. The mixture was pipetted several times to mix well and a 10 mM compound stock solution was prepared. The stock solution was then diluted step by step to a total of ten concentrations: 1 mM, 100 μM, 10 μM, 1 μM, 100 nM, 10 nM, 1 nM, 0.1 nM, and 0.01 nM.
[0142] Mixed solution preparation:
[0143] (1) PDE4B1 stock solution (10 nM): 10 μg of enzyme (MW=109 kDa, purity 70%) was dissolved in 6.419 mL of buffer (25 mM Tris-HCl, pH 8.0, 100 mM sodium chloride, 0.05% Tween-20, 50% glycerol and 3 mM DTT), and the mixture was mixed by pipetting slowly. The mixture was evenly divided into 10 tubes, 641.9 μL / tube. The mixture was reconstituted in an ice bath for 5 min before use, and then reconstituted at room temperature for 3 min. The mixture was mixed by pipetting slowly, and the mixture was mixed by pipetting slowly 3 times before sampling.
[0144] (2) Buffer solution: an aqueous solution containing 61 mM Tris-HCl, 12 mM MgCl2, 61 mM KCl, 6.1 mM TCEP, 0.48 mM PEP, 0.012 mM NADH, and 0.048 mM ATP, pH 8.0, prepare 60 mL.
[0145] (3) Myokinase solution: Take the enzyme suspension stored at 2-8°C, place it at room temperature for 5 min, and slowly beat it to mix it evenly. Accurately measure 65 μL of the enzyme suspension, add 335 μL of buffer to prepare 335 μL of solution, and slowly pipette it to mix it evenly (store on ice).
[0146] (4) Pyruvate kinase solution: Take 0.3 mg of enzyme solid powder stored at -80°C, accurately weigh it, dissolve it in 200 μL buffer, and slowly pipette it to mix it evenly (store on ice).
[0147] (5) Lactate dehydrogenase solution: Take 0.9 mg of enzyme solid powder stored at -80°C, accurately weigh it, dissolve it in 200 μL buffer, and slowly pipette it to mix it evenly (store on ice).
[0148] (6) PDE4B1 solution: Take the aliquoted solution stored at -80°C, reconstitute it on ice for 5 min, and then reconstitute it at room temperature for 5 min. Mix it evenly by slowly pipetting before use.
[0149] (7) cAMP solution (0.032 mM): Take an appropriate amount of cAMP and prepare 2 mL of 0.032 mM solution with Buffer.
[0150] Operation process:
[0151] (1) Prepare a mixed solution in a 96-well plate. First, add 145 μL of buffer, then add 6 μL of myokinase, 3.2 μL of pyruvate kinase, 2 μL of lactate dehydrogenase, and 10 μL of PDE4B1 solution. After each addition, pipette up and down slowly for 3 times to mix evenly.
[0152] (2) Add 10 μL of compound solution of corresponding concentration in sequence, pipette slowly to mix evenly, replace the blank group (without compound) with an equal volume of DMSO, and incubate at room temperature for 5 to 10 minutes.
[0153] (3) Before the assay, add 25 μL of cAMP solution and pipette up and down three times to mix evenly. Replace the wells without cAMP with an equal volume of buffer.
[0154] (4) The excitation wavelength is 355 nM, the emission wavelength is 460 nM, and the measurement is continued for 10 minutes. The measurement is stopped when a plateau appears.
[0155] Data processing: Microsoft Excel 2010 spreadsheet software was used for data processing, and the calculation formula was:
[0156] Inhibition%=(Signal-Min) / (Max-Min)*100%
[0157] Signal: NADH fluorescence intensity in the inhibitor wells; Max: NADH fluorescence intensity in the cAMP-free wells; Min: NADH fluorescence intensity in the compound-free wells.
[0158] The results are shown in Table 1:
[0159] Table 1 Enzyme inhibitory activity of compounds against PDE4B
[0160]
[0161] Conclusion: The inhibitory activity of compound 1 against PDE4B1 is 20 nM, which is 450 times that of the positive drug rolipram and 10 times that of the self-developed positive compound, and has excellent in vitro enzyme activity.
[0162] Test Example 2: Anti-inflammatory activity test of compounds at the in vitro cell level
[0163] Specific test method: The effect of PDE4B inhibitors on the production of inflammatory factor TNF-α was detected by ELISA. The cell density was adjusted to 2×10 5 100 μL per well was inoculated in a 96-well plate and placed at 37°C with 5% CO 2 Incubate in a saturated humidity incubator for 12 hours until the cells adhere to the wall. The experiment was divided into a blank group, an LPS control group, and an experimental group; different concentrations of the test compound (10 μM, 25 μM, and 50 μM) were added to each well of the experimental group and incubated in an incubator for 1 hour; except for the blank group, each group was added with LPS solution (200 ng / mL), and continued to culture for 24 hours, and the culture medium of each well was aspirated into a centrifuge tube, centrifuged at 4°C, 3500 rpm for 10 minutes, and the supernatant was used to determine the level of TNF-α.
[0164] The results are as follows Figure 1 As shown, RAW 264.7 cells were induced by LPS and the inflammatory factor TNF-α was detected. Compound 1 inhibited the inflammatory response of cells in a dose-dependent manner at 1μM, 2μM, and 4μM, showing good anti-inflammatory activity.
[0165] Test Example 3: Results of lung tissue sections in the compound acute lung injury efficacy test
[0166] Specific test method: First, use LPS to induce an acute lung injury model in mice. After the mice are anesthetized (1.25% Avertin, 0.2mL / kg, intraperitoneal injection), the trachea is exposed, and 60μL of lipopolysaccharide solution is instilled into the trachea using a 1mL syringe. After the injection, the mice are stood up and rotated 30 times, then placed upright for 2-3min, the neck is sutured, and placed in an environment with a suitable temperature until they wake up, and then put back into the mouse cage for continued feeding. The model is successfully established. The lung tissue is separated, stored in formalin solution, HE stained, and the lung tissue sections are observed under a microscope and the results are reported.
[0167] The results are as follows Figure 2 As shown in the figure, the model group was more severely congested than the blank group, with more red blood cells, and most alveolar cavities were filled with pink fluid (edema fluid) and a small number of red blood cells, and a small number of gas vacuoles were visible. The positive drug group and the low-dose group of compound 1 were significantly less congested, with fewer red blood cells and only concentrated in some areas, and the gas vacuoles were narrow and long. In the high-dose group of compound 1, cell congestion was rare, red blood cells were rare, the red blood cell aggregation area was not obvious, and the gas vacuoles were small.
[0168] Test Example 4: Results of efficacy index test of compound acute lung injury efficacy test
[0169] Specific test method: The LPS-induced acute lung injury model in mice was established in the same way as in Test Example 3. The method for collecting bronchoalveolar lavage fluid (BALF) is as follows. The mice were killed after removing their eyeballs and taking blood. They were fixed on the operating table. After dissection, the right lung was ligated, and the trachea was intubated and fixed using an intravenous catheter. Then, the left lung bronchi were lavaged with 0.3mL PBS (1×) solution, and the operation was repeated three times. The recovered bronchoalveolar lavage fluid was mixed, centrifuged at 4°C for 10 minutes, and the supernatant was stored at -80°C. The ELISA detection kit was used to determine the content of inflammatory factors TNF-α, IL-1β, and IL-6 in BALF. The mice were dissected, lung tissue was taken, and the lung tissue was homogenized. The MPO and NO activity of the lung tissue were tested according to the instructions for use of the kit.
[0170] The results are as follows Figure 3 As shown, both low and high doses of compound 1 are superior to the positive drug dexamethasone in inhibiting neutrophils and restoring MPO activity and NO levels; in terms of inhibiting inflammatory factors TNF-α, IL-1β, and IL-6, the low dose of WPBL-II-06 is basically the same as the positive drug, while the high dose is better than the positive drug. And from the summary, all indicators show obvious dose dependence, so there is reason to believe that compound 1 has great potential in treating lung inflammation, especially acute lung injury or acute respiratory distress syndrome.
Claims
1. A compound as shown in formula I or a pharmaceutically acceptable salt thereof, in, Z is X is O or NR 5 ; R 1 and R 5 are independently hydrogen, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl; R 2 is hydrogen, unsubstituted or replaced by R 2-1 Substituted C 1-6 Alkyl, unsubstituted or replaced by R 2-2 Substituted 3-6 membered cycloalkyl, unsubstituted or replaced by R 2-3 Substituted 3-6 membered heterocycloalkyl; R 3 and R 4 are independently hydrogen, halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy; R 1-1 and R 2-1 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Carboxyl, -C(=O)-C 1-4 Alkyl, -NHC(=O)-C 1-4 Alkyl or -C(=O)NH-C 1-4 alkyl; R 2-2 and R 2-3 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 carboxyl; R 5 and R 6 are independently halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy; n1 is 0, 1, 2 or 3; n2 is 0, 1, 2, 3 or 4.
2. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, wherein: In the compound represented by Formula I or a pharmaceutically acceptable salt thereof, X is O; R 1 is hydrogen, unsubstituted or replaced by R 1-1 Substituted C 1-6 alkyl; R 2 is hydrogen, unsubstituted or replaced by R 2-1 Substituted C 1-6 alkyl; R 3 and R 4 are independently hydrogen, halogen, hydroxyl, thiol, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy; R 1-1 and R 2-1 Each is independently halogen, hydroxy, amino, nitro, cyano; R 2-2 and R 2-3 are independently halogen, hydroxy, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy.
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: R 1 , R 2 and R 5 In the C 1-6 The alkyl groups are each independently C 1-4 Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and / or, R 2 wherein the 3-6 membered cycloalkyl groups are each independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and / or, R 2 wherein the 3-6 membered heterocycloalkyl groups are each independently a 3-6 membered heterocycloalkyl group having "a heteroatom selected from one or more of N, O and S, and the number of heteroatoms is 1, 2 or 3"; and / or, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 wherein the halogen is independently fluorine, chlorine or bromine; and / or, R 3 , R 4 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and / or, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkyl groups in the haloalkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; and / or, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The halogen in the haloalkyl group is independently fluorine, chlorine or bromine; and / or, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkoxy groups are each independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; and / or, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The alkoxy groups in the haloalkoxy group are each independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; and / or, R 3 , R 4 , R 1-1 , R 2-1 , R 2-2 , R 2-3 , R 5 and R 6 In the C 1-4 The halogen in the haloalkoxy group is independently fluorine, chlorine or bromine.
4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein: The compound shown in formula I is any of the following structures, 5. A pharmaceutical composition comprising a compound as shown in formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, and a pharmaceutically acceptable excipient.
6. Use of the compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5 in the preparation of a medicament as a PDE4 inhibitor.
7. Use of a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5 in the preparation of a medicament for preventing and / or treating a PDE4-related disease, wherein the PDE4-related disease is preferably acute lung injury.
8. Use of a compound as shown in formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5 in the preparation of a medicament for preventing and / or treating a disease, wherein the disease is an inflammatory disease, a fibrotic disease, an injury disease and a central nervous system disease, and the disease is preferably acute lung injury.
9. A compound as shown in formula II or a pharmaceutically acceptable salt thereof, in, Y is nitro or amino; Z, R 5 and n1 is as defined in any one of claims 1-4.
10. A method for preparing a compound as shown in formula I, comprising the following steps: (1) reacting a compound represented by formula IV with a compound represented by formula V to obtain a compound represented by formula II-1; (2) subjecting the compound represented by formula II-1 to reduction reaction to obtain the compound represented by formula II-2; (3) reacting the compound represented by formula II-2 with the compound represented by formula III to obtain the compound represented by formula I; Wherein, A1 and A2 are each independently halogen; Z, R 2 , R 5 , R 6 , n1 and n2 are as defined in any one of claims 1-4.
Citation Information
Patent Citations
6-pyrazole-[1,2,4]triazolo[4,3-a]pyridine-3-amide derivative, preparation method therefor and use thereof in medicine
CN109983015A
Indazole heterocyclic compound with phosphodiesterase 4B inhibitory activity
CN111875594A
Indazole heterocyclic compound with inhibitory activity on phosphodiesterase 4B
CN113563319A
Dihydrothiochromene pyrazole derivative, preparation method thereof and application of dihydrothiochromene pyrazole derivative in medicine
CN113754678A
Triazolopyridine compound as well as preparation method and application thereof
CN114394965A
